At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study to Assess the Efficacy of Durvalumab (MEDI4736) and Tremelimumab Plus Radiotherapy or Ablation in Patients With Metastatic Colorectal Cancer
In Brief
A Phase 2 clinical trial evaluating durvalumab, tremelimumab, and 2 other interventions for Metastatic Colorectal Cancer. Completed, enrolled 25 participants across 1 site.
Detailed Summary
The purpose of this study is to test the safety and effectiveness of two investigational drugs (drugs that are not currently approved by the FDA) given in combination with radiation therapy or ablation.
Study Details
Timeline
Interventions
1500 mg durvalumab via IV infusion
75 mg tremelimumab via IV infusion
Radiotherapy (RT) will be performed using external beam ionizing radiation as standard therapy in accordance with institutional standard practice.
Ablation will be performed percutaneously under image guidance as standard therapy at the discretion of the interventional radiologist in accordance with institutional standard practice.